Latest updates for Dnth
Fresh curated links around DNTH are collected here so marketers can spot useful updates and turn timely ideas into posts faster.
Recent items include:
- Dianthus Therapeutics: A Financed Autoimmune Platform With More Than One Way To Win
- Why This Fund Just Made a $55 Million Bet on Dianthus Amid a 350% Stock Rally
- Dianthus Therapeutics Is Up 320% in a Year. One Major Investor Just Reduced Its Stake but Still Seems Bullish
Post angles to try
Fresh articles and ideas
Recent curated links from global sources. Generate one free draft from any story, then use SocialBu to schedule and refine your content calendar.
Why This Fund Just Made a $55 Million Bet on Dianthus Amid a 350% Stock Rally
This clinical-stage biotech develops antibody therapies for severe autoimmune diseases, targeting rare neuromuscular conditions.
Dianthus Therapeutics Is Up 320% in a Year. One Major Investor Just Reduced Its Stake but Still Seems Bullish
Specializing in monoclonal antibody therapies, this clinical-stage biotech targets severe autoimmune and inflammatory diseases.
Dianthus Therapeutics Is Up 320% in a Year. One Major Investor Just Reduced Its Stake but Still Seems Bullish
Specializing in monoclonal antibody therapies, this clinical-stage biotech targets severe autoimmune and inflammatory diseases.
Dianthus Therapeutics CFO Sells $9.5 Million in Stock
This biotech firm developing antibody therapies for rare diseases disclosed a significant insider sale amid rapid share price gains.
Turn fresh research into a full content calendar
Use SocialBu to discover ideas, generate post drafts, and schedule them across your social channels.